LONG MINI-FUTURE - NOVO-NORDISK B | Real-time Bid/Ask 08:32:14 26/06/2024 pm IST | ||
| 23.56 EUR / 23.7 EUR | +3.14% |
|
| Current month | +9.36% | ||
| 1 month | +6.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 23.79 | +3.84% |
| 25/24/25 | 22.91 | -0.52% |
| 24/24/24 | 23.03 | +1.23% |
| 20/24/20 | 22.75 | +1.20% |
| 19/24/19 | 22.48 | -0.79% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 07:29 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VA76HY |
| ISIN | DE000VA76HY6 |
| Date issued | 12/10/2018 |
| Strike | 128.4 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.79 € |
|---|---|
| Lowest since issue | 0.24 € |
| Spread | 0.01 € |
| Spread % | 0.04% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Certificates
- Certificat
